Aligos Therapeutics Expands Board with New Director Appointments

Aligos Therapeutics (ALGS) just unveiled an announcement.

Aligos Therapeutics, Inc. has expanded its Board of Directors to seven members, adding Heather Preston, M.D., and Margarita Chavez, J.D., as Class II directors, with terms expiring at the 2025 annual stockholders’ meeting. Preston will chair the Nominating Committee, while Chavez will join the Audit Committee. Both will receive a $40,000 annual retainer, stock options, and additional compensation for their committee roles, with no undisclosed relationships affecting their appointments. They will also sign standard indemnification agreements with the company.

For detailed information about ALGS stock, go to TipRanks’ Stock Analysis page.